argenx SE ARGNF Stock
argenx SE Price Chart
argenx SE ARGNF Financial and Trading Overview
argenx SE stock price | 697.42 USD |
Previous Close | 397.9 USD |
Open | 398.1 USD |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 397.9 - 397.9 USD |
52 Week Range | 325 - 398.1 USD |
Volume | 19 USD |
Avg. Volume | 0 USD |
Market Cap | 22.15B USD |
Beta (5Y Monthly) | 0.468582 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 12.76 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
ARGNF Valuation Measures
Enterprise Value | 19.93B USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 34.648006 |
Price/Book (mrq) | 7.8337564 |
Enterprise Value/Revenue | 31.171 |
Enterprise Value/EBITDA | -41.586 |
Trading Information
argenx SE Stock Price History
Beta (5Y Monthly) | 0.468582 |
52-Week Change | 22.43% |
S&P500 52-Week Change | 20.43% |
52 Week High | 398.1 USD |
52 Week Low | 325 USD |
50-Day Moving Average | 362.7 USD |
200-Day Moving Average | 356.61 USD |
ARGNF Share Statistics
Avg. Volume (3 month) | 0 USD |
Avg. Daily Volume (10-Days) | 4 USD |
Shares Outstanding | 55.68M |
Float | 55.16M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 40.38% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -79.96% |
Operating Margin (ttm) | -94.56% |
Gross Margin | -13.17% |
EBITDA Margin | -74.95% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 639.41M USD |
Revenue Per Share (ttm) | 11.57 USD |
Quarterly Revenue Growth (yoy) | 630.19% |
Gross Profit (ttm) | -251786000 USD |
EBITDA | -479285760 USD |
Net Income Avi to Common (ttm) | -511279008 USD |
Diluted EPS (ttm) | -9.19 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.19B USD |
Total Cash Per Share (mrq) | 39.46 USD |
Total Debt (mrq) | 12.43M USD |
Total Debt/Equity (mrq) | 0.44 USD |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | 50.793 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of argenx SE
Country | United States |
State | N/A |
City | Amsterdam |
Address | Laarderhoogtweg 25 |
ZIP | 1101EB |
Phone | 31 10 703 8441 |
Website | https://www.argenx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 843 |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Q&A For argenx SE Stock
What is a current ARGNF stock price?
argenx SE ARGNF stock price today per share is 697.42 USD.
How to purchase argenx SE stock?
You can buy ARGNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for argenx SE?
The stock symbol or ticker of argenx SE is ARGNF.
Which industry does the argenx SE company belong to?
The argenx SE industry is Biotechnology.
How many shares does argenx SE have in circulation?
The max supply of argenx SE shares is 60.99M.
What is argenx SE Price to Earnings Ratio (PE Ratio)?
argenx SE PE Ratio is 54.65674000 now.
What was argenx SE earnings per share over the trailing 12 months (TTM)?
argenx SE EPS is 12.76 USD over the trailing 12 months.
Which sector does the argenx SE company belong to?
The argenx SE sector is Healthcare.